Isabella Bank Corporation (ISBA) Analyst Forecast
Revenue and earnings estimates published by analysts covering Isabella Bank Corporation (ISBA), and the range of their price targets. Everything on this page is a forecast made by other people — DeltaScreener does not produce estimates or targets of its own.
For Isabella Bank Corporation, analysts forecast revenue rising from $75.30T in 2022 to $101.00T in 2027; the average estimate for 2027 earnings per share is $3.95; 1 analyst contribute to these figures. These are forecasts published by analysts, not results.
Analyst price targets
A price target is one analyst's forecast of where a share might trade, usually over twelve months. Targets are frequently revised, they disagree with each other, and they are not a measure of what a company is worth.
Revenue forecast (USD millions)
The spread between low and high is how far analysts disagree, which is usually a better guide than the average alone.
Earnings per share forecast
Isabella Bank Corporation (ISBA) forecast — frequently asked questions
What is the analyst price target for Isabella Bank Corporation?
Analysts covering Isabella Bank Corporation (ISBA) have a consensus price target of $43.00, 10.3% above the current price of $38.97. Published targets range from $43.00 to $43.00. A price target is a forecast, not a measure of value, and targets are revised often.
What are analysts forecasting for Isabella Bank Corporation's earnings?
The average analyst estimate for Isabella Bank Corporation (ISBA) earnings per share in 2027 is 3.95, with individual estimates between 3.95 and 3.95.
How much revenue is Isabella Bank Corporation expected to make?
Analysts forecast Isabella Bank Corporation (ISBA) revenue of $101.00T in 2027, based on 1 published estimates.
How many analysts cover ISBA?
1 analyst contribute estimates for Isabella Bank Corporation (ISBA). Thin coverage makes an average less reliable.
Popular Stocks
Related stock screens
Data for information only, not investment advice. Figures may be delayed or inaccurate; verify against company filings. See our disclaimer.